Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-29

Study Completion Date

2025-04-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators will test a novel protocol for starting BUP (buprenorphine-naloxone) treatment. The BUP microdose induction protocol has participants start very low doses of BUP without stopping other opioids that they are taking. The treatment as usual (TAU) has participants stop other opioids and experience opioid withdrawal before starting BUP. Investigators propose to test BUP microdose inductions vs. TAU in a randomized controlled trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low-dose Buprenorphine Initiation for Opioid Use Disorder

NCT05450718

Opioid Use Disorder

RECRUITING PHASE4

Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing

NCT05307458

Opioid Use Disorder Opioid Withdrawal

UNKNOWN

Buprenorphine Combination Tablet Feasibility - 1

NCT00000298

Opioid-Related Disorders

COMPLETED PHASE2

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

NCT00015171

Heroin Dependence Substance-Related Disorders

COMPLETED PHASE3

Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study

NCT04656899

Opioid-use Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators will conduct a hybrid type 1 effectiveness-implementation study, using a pragmatic, open-label, randomized controlled trial (RCT). Investigators will randomize 270 hospitalized patients with (a) chronic pain and (b) opioid misuse or opioid use disorder (OUD) to a 5-day BUP microdose induction protocol (without stopping full agonists) or 2-day standard induction (with stopping full agonists), and then link participants to outpatient BUP treatment when they are released from the hospital. Study assessment visits will occur at baseline, 1 week, and 1, 3, and 6 months. Assessments will include interviews and urine drug tests to determine whether participants start BUP, continue BUP, have improvements in pain and decrease illicit opioid use. During induction and 3-months of follow-up, investigators will also collect data on mobile devices to assess opioid withdrawal, opioid craving, pain, and anxiety. These data will allow investigators to assess whether BUP microdosing targets of engagement-opioid- and pain-related symptoms-mediate OUD outcomes. Exploratory analyses will also examine pain as a trigger for opioid relapse.

Aim 1: To test the effectiveness of BUP microdose induction (vs. TAU) on OUD outcomes.

H1: The microdose arm (vs. TAU) will have better BUP treatment uptake and retention, and less illicit opioid use.

H2: Improvements in H1 will be mediated by opioid- and pain-related symptoms.

Aim 2: To test the effectiveness of microdosing (vs. TAU) on pain outcomes. H3: The microdose arm (vs. TAU) will have less pain intensity and interference, and improved quality of life.

H4: Improvements in H3 will be mediated by OUD outcomes.

Aim 3: To inform future implementation and dissemination efforts, investigators will:

3a) Examine factors influencing reach, adoption, implementation, and maintenance of BUP microdosing. Investigators will use qualitative and quantitative methods to describe multi-level factors influencing these domains; 3b) Calculate the cost and examine cost-effectiveness of BUP microdosing. H5: Compared with TAU, BUP microdosing will be cost-effective from a societal and a health sector perspective.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Substance Use Disorders Opioid-use Disorder Chronic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BUP microdose induction

Participants in this arm will receive a novel BUP microdose induction protocol.

Group Type EXPERIMENTAL

BUP microdose induction

Intervention Type DRUG

Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).

Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours

Linkage to outpatient BUP treatment

Intervention Type BEHAVIORAL

Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center

Treatment As Usual (TAU)

Participants in this arm will receive standard BUP induction protocol.

Group Type ACTIVE_COMPARATOR

TAU

Intervention Type DRUG

2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours

Linkage to outpatient BUP treatment

Intervention Type BEHAVIORAL

Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BUP microdose induction

Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).

Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours

Intervention Type DRUG

TAU

2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours

Intervention Type DRUG

Linkage to outpatient BUP treatment

Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* Opioid misuse or OUD
* Chronic pain
* Currently taking opioids
* Fluency in English or Spanish
* Planned hospitalization for ≥ 48 hours

Exclusion Criteria

* Current OUD treatment (BUP, methadone, naltrexone)
* Severe alcohol or benzodiazepine use disorder
* Hypersensitivity to BUP or naloxone
* Pain due to malignancy
* Severe untreated mental illness (suicidality, psychosis)
* Pregnancy
* Unable to consent due to pain or cognitive impairment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No